Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00499200
NCT00499200
Completed
Phase 1

A Positron Emission Tomography Study to Assess the Level and Duration of Occupancy of Serotonin-1A Receptors Produced by Single Oral Doses of SRA-444 in Healthy Elderly Subjects and in Subjects With Alzheimer Disease

Wyeth is now a wholly owned subsidiary of Pfizer0 sites42 target enrollmentOctober 2007
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAlzheimer's Disease
InterventionsSRA-444
DrugsSRA-444

Overview

Phase
Phase 1
Intervention
SRA-444
Conditions
Alzheimer's Disease
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment
42
Primary Endpoint
To assess the safety and tolerability of ascending single oral doses of SRA-444 in healthy elderly subjects and subjects with Alzheimer's disease
Status
Completed
Last Updated
17 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSimilar Trials

Overview

Brief Summary

The study will include a preliminary pharmacokinetics (PK) / safety / tolerability evaluation in healthy elderly subjects followed by the Receptor Occupancy (RO) evaluations in healthy elderly subjects and in Alzheimer's Disease (AD) subjects.

Registry
clinicaltrials.gov
Start Date
October 2007
End Date
June 2008
Last Updated
17 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

SRA-444 + Placebo

Experimental; Placebo

Intervention: SRA-444

Outcomes

Primary Outcomes

To assess the safety and tolerability of ascending single oral doses of SRA-444 in healthy elderly subjects and subjects with Alzheimer's disease

Time Frame: after each dose group completion

To obtain PK profiles and determine the level and duration of 5-HT1A RO of SRA-444 by PET

Time Frame: 1 month

Similar Trials

Completed
Early Phase 1
An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine TumoursNeuroendocrine Tumors
NCT04440956Clarity Pharmaceuticals Ltd10
Completed
Phase 1
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057Prostate Cancer
NCT02916537Cancer Targeted Technology20
Terminated
N/A
Study of PET Scans and Serotonin in Hot Flashes TreatmentHot Flashes
NCT00249847Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins5
Completed
N/A
Clinical study using positron emission tomography(PET)brain tumor,epilepsy,multiple sclerosis, neuromyelitis,Duchenne musclar dystrophy,Alzheimer&#39s disease,Down Syndrome,Hydrocephalus
JPRN-UMIN000005626Center for Integrated Human Brain Science, Brain Research Institute, University of Niigata100
Completed
Phase 1
Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic CancerProstate CancerPancreatic CancerBladder Cancer
NCT02092948Jonsson Comprehensive Cancer Center8